In a trial in Africa and India, 4 months of antituberculosis therapy was noninferior to 6 months for children with presumably drug-susceptible, nonsevere disease.
Tuberculosis (TB) affects >1 million children per year worldwide, with significant morbidity and mortality. Current pediatric treatment recommendations have been extrapolated from adult therapeutic trials, although childhood TB is distinct in many ways (e.g., milder symptoms, greater likelihood of smear-negative disease). Administering medication to young children also poses unique challenges.
In this open-label noninferiority trial in Uganda, Zambia, South Africa, and India, investigators enrolled 1204 participants younger than 16 years with nonsevere, symptomatic, and smear-negative (but presumably drug-susceptible) TB; 11% were HIV positive. Nonsevere TB was characterized as respiratory disease limited to one lobe, absence of cavities or …
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose